scout
Opinion|Videos|December 25, 2024

ELECTRA Study: Design

A panelist discusses how the phase 2 ELECTRA trial studies elacestrant in combination with ribociclib as first-line therapy for ER+/HER2– advanced breast cancer in postmenopausal women.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME